BioCentury

1:13 AM GMT, Sep 11, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Top Story

Geron slides on trial discontinuation

Geron Corp. (NASDAQ:GERN) fell $1.62 (56%) to $1.28 on Monday after discontinuing a Phase II trial of imetelstat to treat locally recurrent or metastatic breast cancer following interim data

Read the full 297 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.